Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Leo Pharma has announced that its new drug for the treatment of scalp psoriasis has received approval in 16 European countries.
Subscribe to our email newsletter
The UK will be the first country to market Xamiol. This will take place in the fourth quarter of 2008. Prior to the approval of Xamiol, Leo Pharma has conducted extensive clinical trials involving more than 5,300 people in Europe and the US in order to test the new drug for the treatment of scalp psoriasis.
The clinical results show, inter alia, that Xamiol has a fast effect and eight out of 10 patients concluded that their disease was under control by the end of the treatment.
In June 2008, Taclonex Scalp topical suspension (the name of Xamiol in the US) was approved for the American market, and Leo Pharma’s partner in the US, Warner Chilcott, is already fully engaged in the related sales work.
Gitte Aabo, CEO of Leo Pharma, said: “With the upcoming launch of Xamiol in Europe, Leo has taken a significant step towards realizing our objective to offer patients the best and most complete treatment of their psoriasis.”